Cytosorbents Corp., of Monmouth Junction, N.J.


Extracorporeal cytokine adsorber

Blood purification

Retrospective study reported on the clinical outcomes of the investigational application of Cytosorb in 55 consecutive patients who underwent emergency cardiac surgery between June 2016 and June 2018 while on anti-thrombotic therapy (32 on ticagrelor, 7 on rivaroxaban); bleeding complications during and after surgery were analyzed in both the Cytosorb adsorption and the control (no Cytosorb) groups; in the Cytosorb adsorption group, none of the 39 patients underwent rethoracotomy vs. 6 of 16 patients in the control group; 24-hour median drainage volumes in the Cytosorb group was significantly lower than the control group (p=0.0037) in patients receiving ticagrelor (350 mL vs. 890 mL control) and rivaroxaban (390 mL vs. 600 mL control); control group had multiple bleeding complications vs. the Cytosorb treated group; transfusion of blood products was not necessary for the majority of Cytosorb treated patients, with 31/39 (79.5%) not requiring packed red blood cell transfusions vs. 6/16 (37.5%) controls and 26/39 (66.7%) of Cytosorb treated patients not needing platelets vs. 0/16 (0%) controls


For more information about individual companies and/or products, see Cortellis.

No Comments